SRE
54
5
RHI
49
2
JPM
52
-3
CA
48
4
KMI
44
-9
EBAY
50
-2
TGT
48
4
STI
45
10
SPG
53
2
MHK
43
4
DVA
80
4
TEL
60
3
URI
53
3
CMG
53
-11
AAP
23
3
SBUX
45
-2
FITB
58
5
MMC
65
-2
NUE
47
3
NFLX
59
2
SRE
54
5
RHI
49
2
JPM
52
-3
CA
48
4
KMI
44
-9
EBAY
50
-2
TGT
48
4
STI
45
10
SPG
53
2
MHK
43
4
DVA
80
4
TEL
60
3
URI
53
3
CMG
53
-11
AAP
23
3
SBUX
45
-2
FITB
58
5
MMC
65
-2
NUE
47
3
NFLX
59
2
Financhill
Back

Tarsus Pharmaceuticals 10K Form

Buy
68

TARS
Tarsus Pharmaceuticals

Last Price:
31.96
Seasonality Move:
3.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TARS News And Ratings

See the #1 stock for the next 7 days that we like better than TARS

TARS Financial Statistics

Sales & Book Value

Annual Sales: $17.45M
Cash Flow: $-15.44M
Price / Cash Flow: 0
Annual Sales: $6.63
Price / Book: 5.02

Profitability

EPS (TTM): -4.48000
Net Income (TTM): $-150.07M
Gross Margin: $15.85M
Return on Equity: -69.1%
Return on Assets: -51.79%

Tarsus Pharmaceuticals Earnings Forecast

Key Tarsus Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 4 years for TARS is 90.87%.
  • The Selling, General & Administrative Expenses for TARS have been equal to 623.03% of Gross Profit Margin.
  • The Research & Development expenses have been 288.37% of Revenue.
  • The Interest Expense is -2.37% of Operating Income.
  • The Net Earning history of TARS is -778.89% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Tarsus Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TARS
Website: tarsusrx.com

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 7.03
Quick Ratio: 6.87

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TARS Technical Analysis vs Fundamental Analysis

Buy
68
Tarsus Pharmaceuticals (TARS) is a Buy

Is Tarsus Pharmaceuticals a Buy or a Sell?